Literature DB >> 9851913

Neuroendocrine and immune mediators in prostate cancer progression.

N M Hoosein1.   

Abstract

Cytokines constitute a diverse group of intercellular signaling proteins that regulate local and systemic, immune and inflammatory responses as well as wound healing and hematopoiesis. The proliferation and maturation of cells of the immune system, both normal and malignant, is regulated by cytokines such as the interleukins. Such cytokines may also influence the proliferation and differentiation of other cell types. Prostate epithelial cells differentiate along two pathways, exocrine or neuroendocrine. Elevation in the exocrine marker prostate-specific antigen and/or the neuroendocrine marker chromogranin A in serum has been associated with prostate cancer progression. Interleukin-1 (IL-1) mRNA is expressed by two androgen-insensitive (AI) but not by three androgen-sensitive prostate cancer cell lines. IL-1 inhibits while IL-2 stimulates the growth of the androgen-sensitive LNCaP cell line. Neither affects growth of AI PC-3 or DU-145 cell lines. IL-1 promotes the neuroendocrine phenotype and IL-2 promotes the exocrine phenotype in prostate cancer. The influence of the immune mediators IL-1 and IL-2 on the growth and differentiation of prostate cancer cells and its implication in tumor progression is described herein. Relationship of IL-1 with bone metastasis and the involvement of ss-2 microglobulin in the development and progression of prostate cancer are also discussed.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9851913     DOI: 10.2741/a362

Source DB:  PubMed          Journal:  Front Biosci        ISSN: 1093-4715


  7 in total

1.  Prediction of human protein-protein interaction by a mixed Bayesian model and its application to exploring underlying cancer-related pathway crosstalk.

Authors:  Yan Xu; Wen Hu; Zhiqiang Chang; Huizi Duanmu; Shanzhen Zhang; Zhenqi Li; Zihui Li; Lili Yu; Xia Li
Journal:  J R Soc Interface       Date:  2010-10-13       Impact factor: 4.118

2.  Serum CXCL13 positively correlates with prostatic disease, prostate-specific antigen and mediates prostate cancer cell invasion, integrin clustering and cell adhesion.

Authors:  Shailesh Singh; Rajesh Singh; Praveen K Sharma; Udai P Singh; Shesh N Rai; Leland W K Chung; Carlton R Cooper; Kristian R Novakovic; William E Grizzle; James W Lillard
Journal:  Cancer Lett       Date:  2009-04-17       Impact factor: 8.679

3.  Ki67 staining index and neuroendocrine differentiation aggravate adverse prognostic parameters in prostate cancer and are characterized by negligible inter-observer variability.

Authors:  Sven Gunia; Knut Albrecht; Stefan Koch; Thomas Herrmann; Thorsten Ecke; Volker Loy; Jörg Linke; Michael Siegsmund; Matthias May
Journal:  World J Urol       Date:  2008-04-05       Impact factor: 4.226

4.  Neuropeptide-induced androgen independence in prostate cancer cells: roles of nonreceptor tyrosine kinases Etk/Bmx, Src, and focal adhesion kinase.

Authors:  L F Lee; J Guan; Y Qiu; H J Kung
Journal:  Mol Cell Biol       Date:  2001-12       Impact factor: 4.272

5.  Identification of nucleolar protein No55 as a tumour-associated autoantigen in patients with prostate cancer.

Authors:  A Fosså; R Siebert; H C Aasheim; G M Maelandsmo; A Berner; S D Fosså; E Paus; E B Smeland; G Gaudernack
Journal:  Br J Cancer       Date:  2000-09       Impact factor: 7.640

Review 6.  Association between tumor necrosis factor-alpha gene polymorphisms and prostate cancer risk: a meta-analysis.

Authors:  Liping Ma; Jiangyang Zhao; Taijie Li; Yu He; Jian Wang; Li Xie; Xue Qin; Shan Li
Journal:  Diagn Pathol       Date:  2014-03-25       Impact factor: 2.644

7.  Apolipoprotein E gene polymorphism influences aggressive behavior in prostate cancer cells by deregulating cholesterol homeostasis.

Authors:  Godwin O Ifere; Renee Desmond; Wendy Demark-Wahnefried; Tim R Nagy
Journal:  Int J Oncol       Date:  2013-08-07       Impact factor: 5.650

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.